Today's Healthcare Pulse
Allogene Therapeutics CEO David Chang to step down
Allogene Therapeutics announced that chief executive David Chang will leave his role. The news was reported by STAT+ and echoed in a follow‑up piece covering broader pharma updates.
Also developing:
By the numbers: Boston Scientific invests $1.5B for 34% stake in MiRus
Pharma Pulse: MRNA Legal Wars and the Community Pharmacy Shield
BioNTech has filed a Delaware patent‑infringement lawsuit against Moderna, accusing the latter’s next‑generation COVID vaccine mNEXSPIKE of using BioNTech’s streamlined mRNA design. The disputed shot is projected to generate about 55 % of Moderna’s COVID revenue this season, making the case financially significant. Meanwhile, a new pharmacist‑led PRIME program, combining health coaching with a mobile app, doubled the likelihood that prediabetes patients achieved a clinically relevant 5 % weight loss. The findings highlight community pharmacies as pivotal players in metabolic‑health prevention.
Northwell Temporarily Closes Beds, Cuts Jobs at Long Island Rehabilitation Facility
Northwell Health announced the temporary closure of a 30‑bed unit at its Orzac Center for Rehabilitation in Valley Stream, resulting in the layoff of more than 30 union workers, including licensed practical nurses, certified nursing assistants and physical therapists. The...
Partner Therapeutics Reports P-II (eNRGy) Post-Hoc Results on Zenocutuzumab for NRG1+ NSCLC
Partner Therapeutics presented post‑hoc data from its Phase II eNRGy study of zenocutuzumab (Bizengri) in 27 patients with advanced NRG1‑positive non‑small cell lung cancer who received at least three doses beyond radiographic progression. Eight patients stayed on therapy for six months...
STAT+: Novo Nordisk’s Next-Gen Obesity Drug Stumbles in Comparison Study
Novo Nordisk’s next‑generation obesity drug CagriSema failed to demonstrate non‑inferiority to Eli Lilly’s tirzepatide in the 84‑week REDEFINE 4 study, achieving 20.2% weight loss versus 23.6% for tirzepatide. The open‑label trial showed the two treatments were not statistically equivalent. Following the announcement,...
Operating a New Standard for Life-Saving Pharmaceutical Logistics
Pharmaceutical logistics faces $38 billion annual waste due to fragmented temperature‑controlled networks and customs delays. Frontier Scientific Solutions, based in Wilmington and Shannon, has built a purpose‑built, cGMP‑grade infrastructure that integrates storage, monitoring and direct airside access. By consolidating routes, the...
Transforming Epilepsy Care: How Innovative Implantable Neurotechnology Offers New Hope
PRECISIS GmbH’s EASEE® epicranial neurostimulation system offers a minimally invasive alternative for drug‑resistant focal epilepsy. The implant, positioned under the scalp atop the skull, delivers targeted electrical pulses without opening the skull, achieving a median 68% seizure reduction over two...
J&J Reports Long-Term QUASAR Data for Tremfya in Ulcerative Colitis
Johnson & Johnson released long‑term QUASAR extension data for Tremfya (guselkumab) in ulcerative colitis, showing sustained efficacy through week 140. Clinical remission was achieved by 80.8% of patients, with 78.6% attaining histo‑endoscopic improvement and 53.6% reaching endoscopic remission. Approximately 89% of...
Podcast: Which Pharma and Medtech Companies Came Out on Top in 2025 Revenues?
The 2025 earnings season highlighted a clear hierarchy among healthcare giants, with Eli Lilly and AstraZeneca leading pharma revenue growth and Medtronic and Edwards Lifesciences topping medtech sales. The podcast hosted by Robert Barrie and Ross Law breaks down the financial results, noting...
3D Printed Dissolving Microneedles
Researchers have demonstrated dissolving microneedle (DMN) arrays fabricated using resin‑based 3D‑printed master molds, enabling drug delivery through the inner cheek. The workflow pairs rapid SLA/DLP printing with polymer micromolding, allowing design changes from CAD to mold within hours. Mechanical, dissolution...
STAT+: Pharma Lobbyists Focus on a Surprising New Target: The FDA
Health Secretary Robert F. Kennedy Jr. has pledged to purge industry influence from the FDA, yet the Trump administration’s injection of political priorities has reshaped the agency’s operating environment. Under the current administration, discussions that once were deemed off‑limits between...
How Handheld Ultrasound Systems Improve Point-of-Care Imaging
Handheld ultrasound systems are reshaping point‑of‑care imaging by delivering portable, real‑time diagnostic capability directly at the bedside. Their lightweight design allows clinicians to move quickly between patients, cutting imaging wait times and supporting rapid decision‑making in emergencies. The technology also...
Using Cancer Data to Improve Performance and Reduce Delays
Scotland’s cancer diagnosis pathway is lagging, with only 69.9% of urgent referrals meeting the 62‑day treatment target, well short of the 95% benchmark. The National Framework for Effective Cancer Management (2025) outlines ten steps to streamline care, but implementation remains...
Pulselight Platform Now Available to NHS via £10bn Fortrus Framework
Pulselight has become an authorised partner on the £10 bn Fortrus Digital Enablement Framework, giving NHS trusts a fast, compliant route to acquire its advanced data‑analytics platform. The framework, created by the Countess of Chester Hospital NHS Foundation Trust, streamlines procurement...
AI Bolsters Breast Radiologists’ Cancer Detection Rate, Real World Study Finds
A multi‑center real‑world study of over 100,000 breast imaging exams found that adding iCAD’s AI tool to digital breast tomosynthesis increased cancer detection rates without raising recall rates. Detection of invasive cancers rose 26%, while overall cancer detection per 1,000...
Noted North Carolina Private Radiology Practice Experiences Data Breach
Triad Radiology Associates, a 50‑year‑old North Carolina imaging practice, disclosed a data breach affecting roughly 11,000 patients. The intrusion, detected in February, likely occurred between late July and September and exposed names, addresses, Social Security numbers and bank account details....
Vanda Pharmaceuticals Reports the US FDA’s Approval of Bysanti (Milsaperidone) for Acute Bipolar I Disorder & Schizophrenia
Vanda Pharmaceuticals announced that the U.S. FDA has approved Bysanti (milsaperidone), an active metabolite of iloperidone, as a first‑line therapy for acute manic or mixed episodes in bipolar I disorder and for schizophrenia. The approval is based on demonstrated bioequivalence...
Don’t Overlook Low-Tech Crime in Healthcare
Healthcare organizations focus on high‑tech defenses, yet physical and procedural gaps remain a major source of breaches. Low‑tech incidents such as tailgating, unattended devices, and badge sharing contributed to over 51 million compromised records in 2022. The article outlines practical controls—including...
Beyond Generative AI: Why Healthcare’s Next Leap Depends on Agentic Systems That Can Actually Do the Work
Healthcare’s administrative crisis stems from fragmented, manual workflows rather than mere documentation. While generative AI has streamlined drafting tasks, it fails to automate end‑to‑end processes like prior authorizations, eligibility checks, and denial management. Agentic AI systems, capable of pulling data...
Sickle Cell Gene Therapies Casgevy and Lyfgenia Still Lacking Traction 2 Years In
In February 2024 Vertex and CRISPR Therapeutics launched Casgevy, and bluebird bio (now Genetix Biotherapeutics) launched Lyfgenia as the first FDA‑approved gene therapies for sickle cell disease. Two years later, uptake remains modest—only 64 patients received Casgevy and just over 100...
Beyond Rezdiffra: The 4 Most Promising MASH Pipelines in Play
Madrigal’s Rezdiffra became the first approved therapy for metabolic dysfunction‑associated steatohepatitis (MASH), generating $817 million in revenue within six quarters and prompting a wave of big‑pharma acquisitions focused on FGF21 analogs. In 2025, GSK, Roche and Novo Nordisk spent nearly $10 billion acquiring...
‘Sweet Surprise by Aster’ Raises Awareness on Hidden Sugar as UAE’s Sugar Tax Takes Effect
The UAE introduced a tiered sugar tax on January 1 2026, targeting beverages by sugar content per 100 ml. In response, Aster Clinics UAE opened the Aster Diabetes 360 Care Clinic in Al Qusais and launched the “Sweet Surprise by Aster” campaign, featuring a vending machine...
The Government’s Warning Shot? FDA and HHS Turn Up the Pressure on Compounding
The FDA, backed by HHS, issued a stark warning to compounding pharmacies that market GLP‑1 products such as semaglutide, after Hims & Hers promoted a compounded Wegovy copy. A press release announced intent to restrict non‑approved GLP‑1 APIs and referred...
Women Need Transparent Testosterone Data in Menopause Care
Had a great conversation with Dr. Rebecca Dunsmoor-Su from ovary_active and @mygennev about telemedicine and menopause and many other things. Hope you head to TheVajenda.com for the full interview. Here is a clip of us discussing why women deserve data...
AI's Role in Medicine Explored on NPR's Pulse
Really enjoyed this conversation with @MaikenScott on her @NPR show, @WHYYThePulse, about my book, "A Giant Leap" and how AI will shape the future of medicine. https://t.co/Nw17vwApkg
'It Was Like Buying Groceries' - Woman Calls for Tighter Weight-Loss Jabs Checks
Emma Dyer bought weight‑loss injections online for £115, bypassing any medical assessment, and suffered a severe health collapse within days. Her experience reflects a wider surge, with an estimated 1.6 million UK adults using GLP‑1 drugs such as Mounjaro and Wegovy,...
Vir Biotechnology Inc (VIR) Q4 2025 Earnings Call Transcript
CVRx reported fourth‑quarter 2025 revenue of $16 million, a modest 4% rise, while gross margin improved to 86% driven by higher selling prices and manufacturing efficiencies. The company added 13% more active implanting centers, reaching 252, and expanded U.S. sales territories...
GeneDx Holdings Corp (WGS) Q4 2025 Earnings Call Transcript
GeneDx Holdings reported Q3 2025 revenue of $116.7 million, a 52% year‑over‑year increase, driven by a 66% jump in exome and genome revenue to $98.9 million and 25,702 tests performed. Adjusted gross margin rose to 74% as higher reimbursement rates and a...
Summit Therapeutics Inc (SMMT) Q4 2025 Earnings Call Transcript
Summit Therapeutics reported a strong cash position of $713 million with no debt at the end of 2025, while GAAP operating expenses fell to $225 million despite a rise in non‑GAAP R&D spend. The FDA accepted the Biologics License Application for ivonesumab...
Myriad Genetics Inc (MYGN) Q4 2025 Earnings Call Transcript
Myriad Genetics reported Q4 2025 revenue of $209.8 million, essentially flat year‑over‑year but above its pre‑announced range, while test volume rose 2% to 382,000. Strong double‑digit growth was seen in MyRisk hereditary cancer (14% affected, 11% unaffected), Prolaris prostate cancer (12%...
Tarsus Pharmaceuticals Inc (TARS) Q4 2025 Earnings Call Transcript
Tarsus Pharmaceuticals reported record 2025 net product sales of $451.4 million, driven by XDEMVY adoption, and issued its first full‑year 2026 guidance forecasting $670‑$700 million, implying over 50% revenue growth. The company highlighted a 44% gross‑to‑net discount, a robust DTC campaign that...
Addus Homecare Corp (ADUS) Q4 2025 Earnings Call Transcript
Humana reported adjusted 2025 EPS of $17.14, matching guidance and surpassing the $16.25 estimate. The company added roughly 1 million Medicare Advantage members, a 20% increase, while improving retention by over 500 basis points. New sales were dominated by high‑value channels,...
Immunitybio Inc (IBRX) Q4 2025 Earnings Call Transcript
AbbVie reported a record $61.2 billion in net revenue for 2025, an 8.6% increase that beat guidance despite a $16 billion HUMIRA erosion. Adjusted EPS reached $10, $0.54 above the midpoint, while SKYRIZI and RINVOQ together generated $7.4 billion in Q4, delivering double‑digit...
Hims & Hers Health Inc (HIMS) Q4 2025 Earnings Call Transcript
Hims & Hers Health reported Q4 2025 revenue of $171 million, a 46% year‑over‑year increase, and full‑year revenue of $588 million, up 51% and ahead of guidance. Gross margin rose to 85% in the quarter and 83% for the year, while operating...
HealthStream Inc (HSTM) Q4 2025 Earnings Call Transcript
HealthStream reported record Q3 2025 results, posting $76.5 million revenue, a 4.6% year‑over‑year increase, and new highs in operating income, net income and adjusted EBITDA. Subscription revenue rose 5.7% driven by strong CredentialStream, ShiftWizard and Competency Suite growth, while legacy product...
This AI Can Improve Your Peer Review — and Make It More Polite
Researchers at Stanford introduced the Review Feedback Agent, an AI coach that leverages five large language models to improve peer‑review comments. In a test on roughly 20,000 reviews for the 2025 ICLR conference, the system flagged vague, unprofessional, or fact‑incorrect...
Axsome Therapeutics Inc (AXSM) Q4 2025 Earnings Call Transcript
Axsome Therapeutics reported a 66% revenue surge to $639 million in 2025, driven by strong growth in Auvelity, Sunosi and the newly launched Cymbravo. Net loss narrowed to $183 million, a 35% improvement year‑over‑year, while cash rose to $323 million. The company secured...
Trends and Patterns of Medical Stimulant Use by US Adults
Recent analyses reveal a steady rise in medical stimulant prescriptions among U.S. adults, with a 30% increase between 2013 and 2022. The expansion of telehealth, especially after COVID‑19, contributed to roughly 40% of new adult ADHD initiations, while FDA alerts...
BioMarin Pharmaceutical Inc (BMRN) Q4 2025 Earnings Call Transcript
BioMarin Pharmaceutical raised its fiscal 2025 total revenue guidance, now starting at $3.15 billion, and reaffirmed Voxzogo revenue between $900 million and $935 million. The company lifted non‑GAAP operating margin guidance to 26‑27% and lifted diluted EPS guidance to $3.50‑$3.60. A $221 million IPR&D...
Octave Specialty Group Inc (OSG) Q4 2025 Earnings Call Transcript
Oscar Health reported a 28% revenue jump to $11.7 billion for 2025, driven by strong membership growth that lifted year‑end enrollment to 2 million and a total of 3.4 million members by February 2026. The company posted a $443 million net loss, largely from...
AI Tools Can Design Genomes. Will They Upend How Life Evolves?
Artificial‑intelligence tools are now capable of designing genes that function in mammalian cells and have even generated a fully synthetic virus, marking a watershed for generative biology. In his new book, Adrian Woolfson outlines how computational models could evolve into...
First-of-a-Kind Stem Cell Therapies Set for Approval in Japan
Japan’s health ministry is set to grant conditional approval to two first‑of‑a‑kind regenerative medicines – Amchepry for Parkinson’s disease and ReHeart for severe heart failure – after tiny phase I/II trials involving seven and eight patients respectively. Both drugs are derived...
SI-BONE Inc (SIBN) Q4 2025 Earnings Call Transcript
SI‑BONE reported record Q4 2025 revenue of $56.3 million, a 15% year‑over‑year increase, and full‑year sales of $200.9 million, up 20.2%. The company posted its first positive adjusted EBITDA ($5.1 million) and generated free cash flow for the quarter, narrowing the net loss...
Large Language Model Reads Radiologists' Notes to Flag Patients for Follow-Up Imaging
Researchers at Parkland Health created an AI‑powered tool that leverages a pre‑trained large language model to read radiologists' free‑text notes and automatically flag patients needing follow‑up imaging. In testing on 130,000 studies, the model identified 97% of imaging recommendations and...
Neuro-Symbolic AI and the Quest for Trusted Intelligence in Professional Sectors
Neuro‑symbolic AI merges deep‑learning intuition with symbolic logic, addressing the strict reasoning demands of legal, medical, and financial workflows. By 2026 hybrid models verify outputs against hard‑coded rules, delivering trustworthy, compliant results. The approach powers automated legal discovery, precision medicine...
Mississippi Healthcare System Shuts Down Clinics After Ransomware Attack
The University of Mississippi Medical Center (UMMC) suffered a ransomware attack on February 19 that crippled its Epic EHR, IT network, and phone systems, forcing the shutdown of nearly 30 clinics and a shift to paper‑based documentation. Vice Chancellor LouAnn...
Neutral Molecule Delivers DNA Into Cells, Promising Safer Gene Therapy Approach
Researchers at Tokyo Metropolitan University have engineered a charge‑free polymer‑DNA complex using a thymine‑modified poly(ethylene glycol) (PEG) that binds plasmid DNA via annealing. In mouse models the formulation boosted cellular DNA uptake and gene expression up to 14‑fold compared with...
Louise Milligan Leads FOUR CORNERS Surgeon Scandal
Four Corners aired "Scarred", exposing a Melbourne gynaecologist accused of performing unnecessary laparoscopic surgeries on women in their twenties. Pathology reports often found little or no endometriosis, yet organs and tissue were removed, compromising fertility and causing chronic pain. The...
AI Health Alerts Force Companies to Choose Duty over Silence
In 2026, software doesn’t just store health data - AI allows it to see medical risk before anyone else. When consumers use AI for their health, we are increasingly faced with the dilemma of whether AI companies have a duty...
Novavax Targets S1 and S2 for Broader Protection
Novavax (unlike the mRNA vaccines) generates antibodies to both S1 and S2 units of the spike protein - explaining why it provides somewhat broader protection. I've personally gotten Novavax every time it was available at vaccine time.
CRISPR Unlocks Causal Insights Into Immune Complexity
The complexity of our immune system is daunting. But there's a path to deconvolute it and understand causal relationships. It's CRISPR. open-access @JExpMed https://t.co/QF6Cvkbfz2 https://t.co/OTL2z1fow0